DARK SECRETS: Zydus - The Real Truth

Shares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plunged thirty-six percent year-on-year for the first quarter, despite a nearly twenty-two percent increase in operational revenue. Expenses surged by over forty-one percent. However, the managing director…

Zydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust twenty-two percent increase in operational revenue, reaching eight thousand seventeen crore rupees. The company experienced profitability challenges with an EBITDA reduction of seven point six percent compared to the previous…

Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's…

Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus announced a $166 million acquisition of US-based Assertio. Investor sentiment improved on expectations of capital return and strategic business…

Indian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. Zydus Lifesciences is nearing a US acquisition, while Maruti Suzuki commits to green logistics.

The drug is used to treat high blood pressure in the lungs

MUMBAI: Pharma major Zydus Cadila said on Wednesday it has started supplying its Covid-19 vaccine ZyCoV-D to the Centre, nearly six months after it had been authorised for emergency use in the 12 and above age group.

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art, Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad.